Understanding the Genetic Basis of Parathyroid Carcinoma

[1]  A. Gill,et al.  Negative Parafibromin Staining Predicts Malignant Behavior in Atypical Parathyroid Adenomas , 2014, Annals of Surgical Oncology.

[2]  M. Rugge,et al.  CDC73 mutational status and loss of parafibromin in the outcome of parathyroid cancer , 2013, Endocrine connections.

[3]  S. LeonorMoyano,et al.  Detección inmunohistoquímica de parafibromina en patología de paratiroides , 2013 .

[4]  P. Chanson,et al.  Frequent large germline HRPT2 deletions in a French National cohort of patients with primary hyperparathyroidism. , 2013, The Journal of clinical endocrinology and metabolism.

[5]  M. Nie,et al.  Novel HRPT2/CDC73 Gene Mutations and Loss of Expression of Parafibromin in Chinese Patients with Clinically Sporadic Parathyroid Carcinomas , 2012, PloS one.

[6]  M. Carella,et al.  CDC73 mutations and parafibromin immunohistochemistry in parathyroid tumors: clinical correlations in a single-centre patient cohort , 2012, Cellular Oncology.

[7]  M. Nie,et al.  Expression of Ki-67, galectin-3, fragile histidine triad, and parafibromin in malignant and benign parathyroid tumors. , 2012, Chinese medical journal.

[8]  Ho-Cheol Kang,et al.  Parafibromin immunohistochemical staining to differentiate parathyroid carcinoma from parathyroid adenoma , 2012, Head & neck.

[9]  A. Gill,et al.  Metastatic parathyroid carcinoma initially misdiagnosed as parathyroid adenoma: the role of parafibromin in increasing diagnostic accuracy , 2011, Internal medicine journal.

[10]  A. Gill,et al.  Parathyroid carcinoma: increasing incidence and changing presentation , 2011, ANZ journal of surgery.

[11]  B. Teh,et al.  Downregulation of CASR expression and global loss of parafibromin staining are strong negative determinants of prognosis in parathyroid carcinoma , 2011, Modern Pathology.

[12]  C. Larsson,et al.  Parafibromin and APC as Screening Markers for Malignant Potential in Atypical Parathyroid Adenomas , 2010, Endocrine pathology.

[13]  B. Teh,et al.  Accuracy of combined protein gene product 9.5 and parafibromin markers for immunohistochemical diagnosis of parathyroid carcinoma. , 2009, The Journal of clinical endocrinology and metabolism.

[14]  R. DeLellis,et al.  Primary hyperparathyroidism: a current perspective. , 2008, Archives of pathology & laboratory medicine.

[15]  C. Marcocci,et al.  Re: Familial hyperparathyroidism: surgical outcome after 30 years of follow-up in three families with germline HRPT2 mutations. , 2008, Surgery.

[16]  A. Gill,et al.  Molecular diagnosis of primary hyperparathyroidism in familial cancer syndromes. , 2007, Expert opinion on medical diagnostics.

[17]  A. Gill,et al.  Letter 2: Intraoperative diagnosis and treatment of parathyroid cancer and atypical parathyroid adenoma (Br J Surg 2007; 94: 566–570) , 2007, The British journal of surgery.

[18]  C. Larsson,et al.  Parafibromin immunoreactivity: its use as an additional diagnostic marker for parathyroid tumor classification. , 2007, Endocrine-related cancer.

[19]  C. Marcocci,et al.  Should parafibromin staining replace HRTP2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma? , 2007, European journal of endocrinology.

[20]  G. Ippolito,et al.  Intraoperative diagnosis and treatment of parathyroid cancer and atypical parathyroid adenoma , 2007, The British journal of surgery.

[21]  T. Tuttle,et al.  Trends in the incidence and treatment of parathyroid cancer in the United States , 2007, Cancer.

[22]  A. Gill,et al.  Loss of Nuclear Expression of Parafibromin Distinguishes Parathyroid Carcinomas and Hyperparathyroidism-Jaw Tumor (HPT-JT) Syndrome-related Adenomas From Sporadic Parathyroid Adenomas and Hyperplasias , 2006, The American journal of surgical pathology.

[23]  A. Arnold,et al.  HRPT2 mutational analysis of typical sporadic parathyroid adenomas. , 2005, The Journal of clinical endocrinology and metabolism.

[24]  C. Marcocci,et al.  Genetic analyses of the HRPT2 gene in primary hyperparathyroidism: germline and somatic mutations in familial and sporadic parathyroid tumors. , 2004, The Journal of clinical endocrinology and metabolism.

[25]  Ximing J. Yang,et al.  Loss of Parafibromin Immunoreactivity Is a Distinguishing Feature of Parathyroid Carcinoma , 2004, Clinical Cancer Research.

[26]  J. Carpten,et al.  Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. , 2003, The New England journal of medicine.

[27]  K Hammje,et al.  HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours , 2003, Journal of medical genetics.

[28]  J. Carpten,et al.  HRPT2, encoding parafibromin, is mutated in hyperparathyroidism–jaw tumor syndrome , 2002, Nature Genetics.

[29]  E. Shane,et al.  CHAPTER 33 – Parathyroid Carcinoma , 2001 .

[30]  D. D’amico,et al.  Parathyroid Carcinoma: Sixteen New Cases and Suggestions for Correct Management , 1998, World Journal of Surgery.

[31]  K. Sandelin,et al.  Clinical course of metastatic parathyroid cancer , 1994, World Journal of Surgery.

[32]  Y. Fujimoto,et al.  Diagnosis and treatment of patients with parathyroid carcinoma: An update and review , 1991, World Journal of Surgery.

[33]  Y. Fujimoto,et al.  Localization and surgical resection of metastatic parathyroid carcinoma , 1986, World Journal of Surgery.

[34]  R. Coombs,et al.  Histological diagnosis of carcinoma of the parathyroid gland. , 1984, Journal of clinical pathology.

[35]  D. A. Walker,et al.  Parathyroid carcinoma in familial hyperparathyroidism. , 1977, Journal of clinical pathology.

[36]  J. Le Néel,et al.  [Familial cancer of the parathyroid glands. Importance of angiography in the diagnosis of regional recurrences. Considerations on 2 cases]. , 1975, Journal de chirurgie.

[37]  J. Bilezikian,et al.  Parathyroid carcinoma in familial hyperparathyroidism. , 1974, The American journal of medicine.

[38]  B. Castleman,et al.  Parathyroid carcinoma. A study of 70 cases , 1973, Cancer.

[39]  B. Teh,et al.  Familial hyperparathyroidism: surgical outcome after 30 years of follow-up in three families with germline HRPT2 mutations. , 2008, Surgery.

[40]  T. Fahey.  HRPT2 Mutational Analysis of Typical Sporadic Parathyroid Adenomas , 2006 .

[41]  F. Dagher,et al.  Familial parathyroid carcinoma. , 1972, Le Journal medical libanais. The Lebanese medical journal.